FinanzasMarketWatch.com - Top StoriesNora Redmond
Contenido en inglés
Novo Nordisk’s stock slumps after failed trial — adding to the company’s woes
En resumen
The Danish healthcare company’s stock slumped on Friday after it announced the Phase 3 trial failure.
- Fuente primaria
- MarketWatch.com - Top Stories — Leer artículo original
- Publicado
- Tema
- Finanzas
The Danish healthcare company’s stock slumped on Friday after it announced the Phase 3 trial failure.
Este resumen proviene de MarketWatch.com - Top Stories. Lee el artículo completo en la fuente original.
Referencias
Más en Finanzas
FinanzasMarketWatch.com - Top Stories
Let’s elect candidates who will make the wealthy pay taxes
We can use some of those revenues to make Social Security contributions more equitable.
Alicia H. Munnell
FinanzasMarketWatch.com - Top Stories
‘Don’t get suckered like I did’: I paid $185 to the wrong passport website. Can I get my money back?
“I will file a complaint with the Better Business Bureau.”
Quentin Fottrell
TrumpMarketWatch.com - Top Stories
Rising Medicare Part D premiums could drive more people into Medicare Advantage plans
Medicare Advantage plans could be the winners of a decision by the Trump administration to put an early end to a program that kept the cost of Medicare prescription drug plans…
Jessica Hall
FinanzasMarketWatch.com - Top Stories
Americans are living longer than our retirement system can handle — and many of us are unprepared
Watch out for these 4 major financial pitfalls.
Edd and Cynthia Staton